Varicella-zoster virus.
D000225:Adenine / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D000956:Antigens, Viral; D001089:Arabinose / Q000627:therapeutic use; D002644:Chickenpox / Q000453:epidemiology / Q000503:physiopathology / Q000517:prevention & control; D003561:Cytarabine / Q000627:therapeutic use; D003588:Cytopathogenic Effect, Viral; D006562:Herpes Zoster / Q000453:epidemiology / Q000503:physiopathology; D006566:Herpesviridae Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology / Q000382:microbiology* / Q000473:pathology / Q000503:physiopathology; D014645:Herpesvirus 3, Human / Q000254:growth & development / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D006968:Hypersensitivity, Delayed; D009705:Nucleosides / Q000627:therapeutic use; D014776:Virus Cultivation; D014779:Virus Replication
D000914:Antibodies, Viral; D000956:Antigens, Viral; D009705:Nucleosides; D003561:Cytarabine; D001089:Arabinose; D000225:Adenine